Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $7.25, but opened at $7.81. Aridis Pharmaceuticals shares last traded at $6.86, with a volume of 1,151 shares changing hands.
A number of research firms have issued reports on ARDS. Northland Securities reiterated a “buy” rating and issued a $22.00 target price on shares of Aridis Pharmaceuticals in a research note on Monday, December 7th. Roth Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of Aridis Pharmaceuticals in a research note on Friday, January 22nd. Finally, Zacks Investment Research lowered shares of Aridis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 15th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $15.35.
The stock has a market capitalization of $69.46 million, a price-to-earnings ratio of -2.78 and a beta of 0.18. The business has a fifty day moving average of $7.01 and a 200-day moving average of $7.00.
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its holdings in shares of Aridis Pharmaceuticals by 15.1% in the third quarter. BlackRock Inc. now owns 22,600 shares of the company’s stock valued at $160,000 after buying an additional 2,972 shares in the last quarter. Worth Venture Partners LLC acquired a new position in shares of Aridis Pharmaceuticals in the 4th quarter worth $534,000. Finally, Minot Wealth Management LLC acquired a new stake in shares of Aridis Pharmaceuticals during the fourth quarter worth $803,000. Hedge funds and other institutional investors own 1.81% of the company’s stock.
Aridis Pharmaceuticals Company Profile (NASDAQ:ARDS)
Aridis Pharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Featured Article: What moving averages are used to define a golden cross?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.